Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Progesterone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | SHBG | P04278 | 4/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 3/20 | 1.00 |
| ▸ | AR | P10275 | 3/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Progesterone SCHEMBL15493962 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL16305628 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL14546167 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL13752811 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL7900795 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL23568915 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL418975 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL9120521 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL6661427 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL20342344 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195450-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | HERA HEALTH SOLUTIONS INC. | 2025-06-19 | — | — | US | claimed |
| CN-110198949-B | Process for the preparation of 9 beta, 10 alpha-progesterone (retroprogesterone) | 工业化学有限公司 | 2022-05-10 | — | — | CN | claimed |
| EP-4677063-A1 | METHODS FOR GENERATING ENDOMETRIUM ASSEMBLOIDS | Babraham Institute (GB) | 2026-01-14 | — | — | EP | disclosed |
| US-20250195450-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | HERA HEALTH SOLUTIONS INC. | 2025-06-19 | — | — | US | disclosed |
| US-12274797-B2 | Bioerodible drug delivery implants | HERA HEALTH SOLUTIONS INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20250092360-A1 | METHODS AND COMPOSITIONS FOR GENERATING SOMATOSTATIN+ INTERNEURONS FROM HUMAN FOREBRAIN NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2025-03-20 | — | — | US | disclosed |
| US-12171779-B2 | Regulated drug delivery via controlled degradable chondroitin sulfate particles | UNIVERSITY OF SOUTH FLORIDA (US) | 2024-12-24 | — | — | US | disclosed |
| WO-2024184624-A1 | METHODS FOR GENERATING ENDOMETRIUM ASSEMBLOIDS | BABRAHAM INSTITUTE (GB) | 2024-09-12 | — | — | WO | disclosed |
| EP-4423252-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN FOREBRAIN NEURAL PROGENITOR CELLS AND FOR MATURATION THEREOF TO PARVALBUMIN+ INTERNEURONS | Trailhead Biosystems Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-4404914-A1 | REFILLABLE IMPLANTABLE DEVICE FOR DELIVERING A CONTRACEPTIVE AGENT | Celanese EVA Performance Polymers LLC (US) | 2024-07-31 | — | — | EP | disclosed |
| CN-117999067-A | Refillable implantable device for delivering contraceptive | 塞拉尼斯伊娃高性能聚合物公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20070212751-A1 | Microbial method for the 11beta hydroxylation of 9beta, 10alpha-steriods | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| WO-2007082891-A1 | PROCESS FOR THE PREPARATION OF 11BETA-HYDR0XY-9BETA, 10ALPHA -STEROIDS EMPLOYING AMYCOLATOPSIS MEDITERRANEI CELLS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007082891-A1 | PROCESS FOR THE PREPARATION OF 11BETA-HYDR0XY-9BETA, 10ALPHA -STEROIDS EMPLOYING AMYCOLATOPSIS MEDITERRANEI CELLS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007039544-A1 | NOVEL C18 MODIFIED RETROSTEROIDS AS PROGESTERONE RECEPTOR MODULATOR COMPOUNDS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039544-A1 | NOVEL C18 MODIFIED RETROSTEROIDS AS PROGESTERONE RECEPTOR MODULATOR COMPOUNDS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-04-12 | — | — | WO | disclosed |
| US-20070082876-A1 | Novel C18 modified retrosteroids as progesterone receptor modulator compounds | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-04-12 | — | — | US | disclosed |
| US-20070082876-A1 | Novel C18 modified retrosteroids as progesterone receptor modulator compounds | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-04-12 | — | — | US | disclosed |
| US-20070082876-A1 | Novel C18 modified retrosteroids as progesterone receptor modulator compounds | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-04-12 | — | — | US | disclosed |
| US-3956316-A | PROGESTATIONAL AND SALT-RETAINING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12171779-B2 | Regulated drug delivery via controlled degradable chondroitin sulfate particles | CD44, CSGALNACT1, ALG1 | PGR 756/4885CYP3A4 3652/4885LMNA 4323/4885 |
| US-20070082876-A1 | Novel C18 modified retrosteroids as progesterone receptor modulator compounds | HSD17B11, CYP19A1, CYP17A1 | PGR 4/4885CYP3A4 789/4885LMNA 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.